CCR1 and relapsing-remitting multiple sclerosis: Previously published studies reported that CCR1 inhibition was effective in reducing collagen induced arthritis in mice and alters cytokine networks (Amat et al., 2006b), in decreasing inflammation in mice with glomerulosclerosis and nephrotic syndrome (Vielhauer et al., 2004) in suppressing pro-inflammatory expression and up-regulating anti-inflammatory mediators in a mouse model of relapsing-remitting multiple sclerosis (Ansari et al., 2022).